

FORM PTO-1449	DOCKET NO.: 158404 (71432)	SERIAL NO.: 10/717,434
INFORMATION DISCLOSURE STATEMENT	APPLICANT(S): c. Thru et al.	
	FILING DATE: November 18, 2003	GROUP NO.: 1632 1635

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO
TV	AA	WO 99/14226	03/25/99	WIPO			
TV	AB	WO 98/39352	09/11/98	WIPO			No

## OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

TV	AC	Nielsen et al., <i>J. Chem. Soc., Perkin Trans. I</i> , pp. 3423-3433 (1997).
	AD	Nielsen et al., <i>Chem. Commun.</i> , 9:825-826 (1997).
	AE	Christensen et al., <i>J. Am. Chem. Soc.</i> , 120:5458-5463 (1998).
	AF	Koshkin et al., <i>J. Org. Chem.</i> , 63(8):2778-2781 (1998).
	AG	Koshkin et al., <i>J. Am. Chem. Soc.</i> 120(50):13252-13253 (1998).
	AH	Kumar et al., <i>Bioorg. &amp; Med. Chem. Lett.</i> , 8:2219-2222 (1998).
	AI	Braasch et al., <i>Biochemistry</i> , 41(14):4503-4510 (2002).
	AJ	Crinelli et al., <i>Nucl. Acid. Res.</i> , 30(11):2435-2443 (2002).
	AK	Elayadi et al., <i>Biochemistry</i> , 41:9973-9981 (2002).
	AL	Jacobsen et al., <i>Nucl. Acid. Res.</i> , 30(19), in press (2002).
	AM	Kurreck et al., <i>Nucl. Acid. Res.</i> , 30(9):1911-1918 (2002).
	AN	Obika et al., <i>Bioorg. &amp; Med. Chem.</i> , 9:1001-1011 (2001).
	AO	Braasch et al., <i>Chem. &amp; Biol.</i> , 55:1-7 (2000).
	AP	Wahlestedt et al., <i>PNAS</i> , 97(10):5633-5638 (2000).
	AQ	Freier et al., <i>Nucl. Acid Res.</i> , 25(22):4429-4443 (1997).
	AR	Cook, <i>Nucleosides &amp; Nucleotides</i> , 18(6&7), 1141-62 (1999).
	AS	Singh, <i>J. Org. Chem.</i> , 63:6078-6079 (1998).
	AT	Singh et al. <i>J. Org. Chem.</i> , 63:10035-10039 (1998).
	AU	Rajwanshi et al., <i>J. Chem Commun.</i> , pp. 2073-2074 (1999).
	AV	Hakansson et al., <i>Bioorg Med Chem Lett</i> , 11:935-938 (2001).
	AW	Rajwanshi et al., <i>Chem Commun.</i> , pp. 1395-1396 (1999).
	AX	Wengel et al., <i>Nucleosides, Nucleotides &amp; Nucleic Acids</i> , 20(4-7):389-396 (2001).
	AY	Rajwanshi et al., <i>Angew. Chem. Int. Ed.</i> , 39(9):1656-1659 (2000).
	AZ	Petersen et al., <i>J. Am. Chem. Soc.</i> , 123:7431-7432 (2001).
	BA	Sørensen et al., <i>J. Am. Chem. Soc.</i> , 124(10):2164-2176 (2002).
	BB	Vester et al., <i>J. Am. Chem. Soc.</i> , 124(46):13682-13683 (2002).
	BC	Arzumanov et al., <i>Biochemistry</i> 40:14645-14654 (2001).
	BD	Zamecnik et al., <i>PNAS</i> , 75(1):280-284 (1978).
	BE	Bennet et al., <i>Biochim. Biophys. Acta</i> , 1489:19-30 (1999).
	BF	Crooke, <i>Biotechnol. Genet. Eng. Rev.</i> , 15:121-57 (1998).
	BG	Wengel, <i>J. In Antisense Drug Technology; Principles</i> , pp. 339-355 (2001).
	BH	Simeonov et al., <i>Nucleic Acids Research</i> , 30(17), in press (2002).
	BI	Childs et al., <i>PNAS</i> , 99(17):11091-11096 (2002).

Examiner: Tracy D. Williams	Date: 10/20/05
-----------------------------	----------------



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/717,434-Conf. #7002
				Filing Date	November 18, 2003
				First Named Inventor	Charlotte A. Thru
				Art Unit	NTA 1635
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	58404(1432)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (# known)			


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (# known)				
TV	BA	WO-01/48190-A2	07-05-2001	Exiqon A/S		
	BB	WO-00/66604-A2	11-09-2000	Exiqon A/S		
	BC	WO-01/25478-A1	04-12-2001	Exiqon A/S		
	BD	WO-01/25248-A2	04-12-2001	Exiqon A/S		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
TV	CA	L. KIENICKE et al., "alpha-L-RNA (alpha-L-ribo Configured RNA): Synthesis and RNA-Selective Hybridization of alpha-L-RNA/alpha-L-LNA Chimera." <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , Vol. 12, 4, 2002, pages 593-596	
TV	CB	M. FRIEDEN et al., "Expanding the design horizon of antisense oligonucleotides with alpha-L-LNA." <i>Nucleic Acids Research</i> , Vol. 31, No. 21, 2003, pages 6365-6372	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	10/20/05
-----------------------	---	--------------------	----------

463214